Mika is unique for each person.
It combines AI-powered Monitoring and Coaching.
Monitoring
Daily Check-Ups allow continuous tracking of distress levels and symptoms.
It is based on validated symptom scales such as the CTCAE criteria and the distress thermometer. When certain thresholds are exceeded, users receive a warning that they should go and see their doctor.
The symptom data can be downloaded and exported in an interoperable format.
Coaching: Information
and Motivation
The coaching section provides users with the information they need. This includes over 800 multi-media elements such as articles or videos on 8 different topics. Each content is written by experts and goes through a rigorous validation process.
In addition, there are so-called “Journeys“: interactive courses developed with experts, such as psycho-oncologists. The courses include regular exercises to help patients cope with their situation.
Articles, Videos
& Exercises
Mika is smart
The Mika app constantly analyses the user profile including data about the disease, therapy, personal details and from daily monitoring of symptoms and wellbeing. In addition, the system learns from user behaviour and remembers the interests and preferences of each user.
Mika also analyses its database about the behaviour of other users from the past.
Through this data analysis, Mika provides specifically personalised content.
Clinical Results: RCT Study at Charité
We conducted a 12-week pilot study at the gynaecological department of the internationally renowned medical institute, Charité Berlin about the effects of therapy support with Mika:
A reduction in fatigue of 23% was observed in an intervention group of gynaecological patients who used Mika. Patients within that group receiving chemotherapy showed a 31% reduction in fatigue.
Ongoing studies
| Study | Onkodigitrial I | Onkodigitrial II | SOFIA |
|---|---|---|---|
| Status | Enrolling | Enrollment complete | Enrolling |
| DKRS Study number | DRKS00026038 | DRKS00021064 | |
| Study design | RCT | RCT | RCT |
| Study population | 524 adult patients with malignant tumor | 250 adults patients with malignant tumor (diagnosis within the last 5 years) | 70 adult patients with cancer receiving immunotherapy |
| Intervention | 16 weeks Mika-App (+ TAU) | 12 weeks Mika-App (+ Tau) plus 9 months for an additional longitudinal follow-up | 12 & 24 weeks TAU + SOFIA / Mika App plus |
| Control | TAU (+ Mika-App after 12 weeks) | TAU | TAU |
| Primary endpoint | Health-realted quality of life (SF-8) | Psychological stress reduction using DT VAS at week 12 | HRQoL (EORTC QLQ C30,) |
| Secondary endpoint | Psychological distress (DT), fatigue (EORTC-OLQ-C30), depression (PHQ-9), health literacy (HELP),usage time, digital competence, self-management (Hei-Q), adherence (ABQ) | Improvement quality of life (CGI-I), fatigue reduction (FACIT-F), depression/anxiety reduction (HADS-D), adherence/compliance, patient sovereignty, health competence | PHQ9-D, GAD7; NCCN Distress-Barometer, CBI-B-D, SCNS-SF34-D, FAPI; evaluation of the treatment under using SOFIA-Monitoring by the physicians |